Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

SLU Explores Best Ways To Use Standard TB Vaccine
In a study funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Saint Louis University"s Center for Vaccine Development is investigating whether the standard vaccine used in foreign countries against tuberculosis offers better protection as a shot, drink or combination of both.
generic viagra online
Paladin Labs Announces Canadian Launch Of Twinject(R) TwinpackTM For Anaphylaxis
Good news for the 1.3 million Canadian patients at risk for anaphylaxis, as Paladin Labs Inc. (TSX:PLB), a leading Canadian specialty pharmaceutical company, announced the Canadian launch of Twinject® TwinpackTM, making it more convenient for people to manage this potentially life threatening condition.
News of the day
Efficacy Of Tecarfarin Mirrors Earlier Studies While Primary Endpoint Missed
ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced results from its Phase 2/3 clinical trial, EmbraceAC, comparing its novel anticoagulant agent tecarfarin (previously ATI-5923) with the leading oral anticoagulant warfarin. In this trial, tecarfarin demonstrated efficacy essentially the same as in earlier Phase 2 studies but did not achieve the primary endpoint of superiority over warfarin, as measured by time in therapeutic range (TTR). This was due to the virtually unprecedented performance of warfarin in this trial. Using the International Normalized Ratio (INR), which is the standard measure of anticoagulation to evaluate TTR, the patients in the trial who were administered tecarfarin stayed within the target therapeutic range 74.0% of the time treated as compared to those patients receiving warfarin who stayed within the target therapeutic range 73.2% of the time (p=0.506). The result for the warfarin group was unexpected based upon the extensive history of prior studies and published literature for the drug. Tecarfarin appeared to be well tolerated by the patients in this Phase 2/3 clinical trial.
Cardiovascular

New York Times Examines Pilot Program To Fight Drug-Resistant TB In South African Communities

The New York Times examines a Doctors Without Borders pilot program to fight drug-resistant tuberculosis in South Africa that allows patients to stay in their homes rather than be isolated in hospital during treatment. The program, which is supported by the city of Cape Town and the Western Cape Province, aims to "show that such patients can be successfully treated in an impoverished community ò€¦ even while they are still infectious," the New York Times writes. Cheryl McDermid, a Canadian doctor with Doctors Without Borders, manages the program in the town of Khayelitsha. "About a fifth of the patients enrolled last year died, either while waiting weeks for a diagnosis or after treatment began. One in six of those who started treatment dropped out. But most patients have stuck with it and are now no longer infectious," the newspaper writes. McDermid said although it is still too early to know what the treatment success rate will be, there is no evidence that patients in the program are infecting the people who live with them. "Drug-resistant tuberculosis is a mounting global health threat," according to the newspaper. The disease is a "particularly virulent problem in Africa, where AIDS has heightened the vulnerability of millions," the New York Times writes. According to Paul Nunn, coordinator of the drug-resistance unit in the WHO"s TB department, ten African countries do not even have laboratories that can detect drug-resistant TB (Dugger, 7/28). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009